• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    $1M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

    12/29/23 6:36:46 AM ET
    $ANNX
    $SRAX
    $VRME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary
    Get the next $ANNX alert in real time by email

    The Dow Jones index closed higher by over 50 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    SRAX

    • The Trade: SRAX, Inc. (OTC:SRAX) CEO Christopher Miglino acquired a total of 15,000 shares an average price of $0.05. To acquire these shares, it cost around $750.
    • What’s Happening: The company’s stock dipped 77% over the past month.
    • What SRAX Does: SRAX Inc is a financial technology company that unlocks data and insights for publicly traded companies.

    VerifyMe

    • The Trade: VerifyMe, Inc. (NASDAQ:VRME) CEO Adam Stedham acquired a total of 14,441 shares at an average price of $1.04. To acquire these shares, it cost around $15,019.
    • What’s Happening: VerifyMe board approved a share repurchase program of up to $500,000.
    • What VerifyMe Does: VerifyMe Inc is a technology solutions company based in the United States. It markets a broad patent portfolio that includes patents in the field of authenticating products, people, and financial transactions.

    Check This Out: Wall Street's Most Accurate Analysts Say Buy These 3 Industrials Stocks With Over 3% Dividend Yields

    Annexon

    • The Trade: Annexon, Inc. (NASDAQ:ANNX) Director Muneer A Satter acquired a total of 350,000 shares at an average price of $2.88. The insider spent around $1.01 million to buy those shares.
    • What’s Happening: Annexon reported pricing of $125 million public offering of common stock.
    • What Annexon Does: Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye.

     

    Don’t forget to check out our premarket coverage here

    Get the next $ANNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANNX
    $SRAX
    $VRME

    CompanyDatePrice TargetRatingAnalyst
    Annexon Inc.
    $ANNX
    12/23/2025$16.00Buy
    Chardan Capital Markets
    Annexon Inc.
    $ANNX
    3/1/2024$11.00Neutral → Overweight
    JP Morgan
    Annexon Inc.
    $ANNX
    12/21/2023$4.00 → $6.00Neutral → Buy
    BofA Securities
    Annexon Inc.
    $ANNX
    10/30/2023$11.00Overweight
    Wells Fargo
    Annexon Inc.
    $ANNX
    5/26/2023$8.00 → $3.00Buy → Neutral
    BofA Securities
    Annexon Inc.
    $ANNX
    5/25/2023$19.00 → $9.00Overweight → Neutral
    JP Morgan
    Annexon Inc.
    $ANNX
    9/16/2022$12.00Buy
    Jefferies
    Annexon Inc.
    $ANNX
    9/9/2022$15.00Buy
    BTIG Research
    More analyst ratings

    $ANNX
    $SRAX
    $VRME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Carson William H.

    4 - Annexon, Inc. (0001528115) (Issuer)

    4/14/26 4:16:40 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/12/26 4:31:34 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CHIEF SCIENTIFIC OFFICER Artis Dean Richard sold $32,004 worth of shares (5,894 units at $5.43), decreasing direct ownership by 3% to 180,093 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/4/26 4:30:41 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $SRAX
    $VRME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Annexon with a new price target

    Chardan Capital Markets initiated coverage of Annexon with a rating of Buy and set a new price target of $16.00

    12/23/25 8:41:58 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon upgraded by JP Morgan with a new price target

    JP Morgan upgraded Annexon from Neutral to Overweight and set a new price target of $11.00

    3/1/24 7:27:25 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon upgraded by BofA Securities with a new price target

    BofA Securities upgraded Annexon from Neutral to Buy and set a new price target of $6.00 from $4.00 previously

    12/21/23 6:41:39 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $SRAX
    $VRME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/12/26 4:31:34 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $18,394 worth of shares (4,115 units at $4.47), increasing direct ownership by 9% to 50,290 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:14 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $SRAX
    $VRME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

    BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 11:45 a.m. ET. A live webcast of the event can be accessed under the ‘Events & Presentations' section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. Ab

    4/8/26 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VerifyMe Reports Fourth Quarter 2025 Financial Results

    Cash of $4.4 million and short-term note receivable of $2.0 million as of December 31, 2025 Cash flow provided by operations of $0.6 million in 2025, compared to $0.9 million in 2024 2025 annual revenue of $16.4 million, compared to $24.2 million in 2024; with fourth quarter revenue of $2.4 million, compared to $7.7 million in Q4 2024 2025 annual gross profit of $6.3 million or 39%, compared to $8.7 million or 36% in 2024; gross profit of $1.2 million or 49% in Q4 2025, compared to $2.4 million or 32% in Q4 2024 2025 annual net loss of $4.9 million (including $4.3 million of one-time adjustments), compared to a net loss of $3.8 million (including $1.6 million of one-time adjust

    3/30/26 5:20:00 PM ET
    $VRME
    EDP Services
    Technology

    Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); U.S./European FORWARD Study Data Expected to Support Planned BLA Submission in 2026 ANX1502 Advancing as First Oral C1 Inhibitor for Autoimmune Disease; Proof-of-Concept (POC) Data Anticipated in 2026 Strong Balance Sheet with Cash, Cash Equivalents and Short-Term Investments of Approximately $238.3 Million as of December 31, 2025, and Anticipated Runway into Second Half 2027 BRISBANE, Calif., March 30,

    3/30/26 4:01:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $SRAX
    $VRME
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    March 22, 2024 - FDA Roundup: March 22, 2024

    For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

    3/22/24 5:02:42 PM ET
    $SNAP
    $SRAX
    Computer Software: Programming Data Processing
    Technology
    Advertising
    Consumer Discretionary

    November 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

    For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains

    11/9/23 2:30:20 PM ET
    $SRAX
    $SNAP
    Advertising
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    $ANNX
    $SRAX
    $VRME
    SEC Filings

    View All

    SEC Form 425 filed by VerifyMe Inc.

    425 - VerifyMe, Inc. (0001104038) (Subject)

    4/16/26 5:20:24 PM ET
    $VRME
    EDP Services
    Technology

    VerifyMe Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - VerifyMe, Inc. (0001104038) (Filer)

    4/16/26 5:20:19 PM ET
    $VRME
    EDP Services
    Technology

    SEC Form PRE 14A filed by Annexon Inc.

    PRE 14A - Annexon, Inc. (0001528115) (Filer)

    4/16/26 4:06:13 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $SRAX
    $VRME
    Financials

    Live finance-specific insights

    View All

    VerifyMe Reports Third Quarter 2025 Financial Results

    Revenue of $5.0 million in Q3 2025, compared to $5.4 million in Q3 2024(1) Gross profit of $2.1 million or 41% in Q3 2025, compared to $1.9 million or 35% in Q3 2024 Net loss ($3.4) million in Q3 2025, including $3.9 million of one-time adjustments, compared to a net loss of ($2.4) million, including $1.8 million of one-time adjustments in Q3 2024 Adjusted EBITDA(2) of $0.8 million in Q3 2025, compared to $0.2 million in Q3 2024 Cash of $4.0 million as of September 30, 2025, with cash provided by operations of $0.2 million in Q3 2025, compared to $0.0 million in Q3 2024. Short-term note investment of $2.0 million with regular quarterly interest payments VerifyMe, Inc. (NA

    11/17/25 8:00:00 AM ET
    $VRME
    EDP Services
    Technology

    Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; Continued FDA Discussions Regarding Generalizability Package in Support of BLA Filing Topline ARCHER II Pivotal Data for Vonaprument in Dry AMD with GA on Track for Second Half of 2026; Potential to Be the First Approved Vision Sparing Therapy for the Treatment of Eight Million GA Patients Worldwide ANX1502 Cold Agglutinin Disease (CAD) Proof of Concept Study Ongoing with Expected 2026

    11/10/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VerifyMe to Report Third Quarter 2025 Financial Results on November 17, 2025

    VerifyMe, Inc. (NASDAQ: VRME) ("VerifyMe," "we," "our," or the "Company") which provides brand owners time and temperature sensitive logistics, and brand protection and enhancement solutions, announced today that it has scheduled an investor conference call and webcast on November 17, 2025 at 9:00 a.m. Eastern Time. Prepared remarks regarding the Company's third quarter financial and operational results will be followed by a question and answer period with the executive management team. The conference call may be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=LBAE0mrW or by calling +1 (844) 763-8274 within the US, or +1 (412) 717-9224 international

    11/10/25 8:05:00 AM ET
    $VRME
    EDP Services
    Technology

    $ANNX
    $SRAX
    $VRME
    Leadership Updates

    Live Leadership Updates

    View All

    Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Kind Oral C1s Inhibitor Exposure Exceeded Target Concentration in Fasted Patients; Evaluation in Relation to Food Intake Ongoing in Proof-of-Concept CAD Study, Update Expected by Year-end 2025 $227 Million i

    8/14/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

    Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to Significantly Preserve Vision and Central Retinal Photoreceptors Critical for Visual Acuity Enrollment of Phase 3 ARCHER II Trial Expected to be Completed in Q3 2025, with Topline Data Expected in Second Half of 2026 BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-medi

    6/18/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

    Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

    4/9/25 7:00:00 AM ET
    $ANNX
    $LUMO
    $GRAY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $SRAX
    $VRME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 7:21:59 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 6:46:41 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 5:30:27 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care